Drugs / TP10
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02302755 | Nov 2014 → Oct 2016 | dense deposit disease | University of Iowa | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 21 trial | ||||||
| Phase 2 | NCT00082121 | Apr 2004 → Dec 2005 | aortic valve insufficiency, coronary atherosclerosis, mitral valve insufficiency, myocardial ischemia | Avant Immunotherapeutics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TP10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00082121 ↗ |
| Action | Inhibit | “blocks complement release” NCT00082121 ↗ |
| Route | Intravenous | “intravenous drip infusion” NCT02302755 ↗ |